TY - JOUR
T1 - Revised meta-analysis and pooled estimate of audio-vestibular symptoms associated with COVID-19
AU - Lough, Melanie
AU - Almufarrij, Ibrahim
AU - Whiston, Helen
AU - Munro, Kevin
N1 - Funding Information:
This project was supported by the NIHR Manchester Biomedical Research Centre. We would like to thank the following authors who responded to our requests for information: Dr Elizabeth T. Cirulli, Dr. Amiel Dror, Dr Yvonne Goërtz, Dr Leila Karimi, Dr Mehran Karimi, Dr Jerome R. Lechien, Dr Davide Pisani, Dr Haitham Saeed, and Dr Saee Savtale.
PY - 2022/8/1
Y1 - 2022/8/1
N2 - A rapid review of audio-vestibular symptoms relating to SARS-CoV-2 and COVID-19 appeared in IJA in 2020 (Almufarrij, Uus, and Munro 2020), but the first systematic review and meta-analysis appeared in 2021 (Almufarrij and Munro 2021). Their pooled prevalence estimates of hearing loss, tinnitus and rotatory vertigo, based primarily on retrospective recall of symptoms, were 7.6% (CI: 2.5–15.1), 14.8% (CI: 6.3–26.1) and 7.2% (CI: 0.01–26.4), respectively. Almufarrij and Munro urged caution when interpreting these data because it was not always clear within each study if the symptom associated with SARS-CoV-2 and COVID-19 was new or a change (i.e. the prevalence may have been over-estimated if the symptoms were present before, and unchanged by, COVID-19). With this in mind, we reviewed the 28 studies in their meta-analysis and attempted to contact authors of individual studies where there was uncertainty or missing data. We then conducted a new meta-analysis using more conservative inclusion criteria.
AB - A rapid review of audio-vestibular symptoms relating to SARS-CoV-2 and COVID-19 appeared in IJA in 2020 (Almufarrij, Uus, and Munro 2020), but the first systematic review and meta-analysis appeared in 2021 (Almufarrij and Munro 2021). Their pooled prevalence estimates of hearing loss, tinnitus and rotatory vertigo, based primarily on retrospective recall of symptoms, were 7.6% (CI: 2.5–15.1), 14.8% (CI: 6.3–26.1) and 7.2% (CI: 0.01–26.4), respectively. Almufarrij and Munro urged caution when interpreting these data because it was not always clear within each study if the symptom associated with SARS-CoV-2 and COVID-19 was new or a change (i.e. the prevalence may have been over-estimated if the symptoms were present before, and unchanged by, COVID-19). With this in mind, we reviewed the 28 studies in their meta-analysis and attempted to contact authors of individual studies where there was uncertainty or missing data. We then conducted a new meta-analysis using more conservative inclusion criteria.
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:000688310000001&DestLinkType=FullRecord&DestApp=WOS
UR - http://www.scopus.com/inward/record.url?scp=85113549158&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/effe52d7-dfbf-350d-a136-fe9ba9bbbb7d/
U2 - 10.1080/14992027.2021.1962552
DO - 10.1080/14992027.2021.1962552
M3 - Letter
C2 - 34431432
SN - 1499-2027
VL - 61
SP - 705
EP - 709
JO - International Journal of Audiology
JF - International Journal of Audiology
IS - 8
ER -